Log in
NASDAQ:ALNA

Allena Pharmaceuticals Stock Forecast, Price & News

$1.32
-0.02 (-1.49 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.28
Now: $1.32
$1.36
50-Day Range
$1.10
MA: $1.34
$1.54
52-Week Range
$0.53
Now: $1.32
$6.30
Volume384,604 shs
Average Volume781,932 shs
Market Capitalization$50.32 million
P/E RatioN/A
Dividend YieldN/A
Beta2.68
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.
Read More
Allena Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.72 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALNA
CUSIPN/A
Phone617-467-4577

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.73 per share

Profitability

Net Income$-47,340,000.00

Miscellaneous

Employees34
Market Cap$50.32 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$1.32
-0.02 (-1.49 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions

How has Allena Pharmaceuticals' stock been impacted by Coronavirus?

Allena Pharmaceuticals' stock was trading at $1.26 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALNA stock has increased by 4.8% and is now trading at $1.32.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Allena Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Allena Pharmaceuticals
.

When is Allena Pharmaceuticals' next earnings date?

Allena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Allena Pharmaceuticals
.

How were Allena Pharmaceuticals' earnings last quarter?

Allena Pharmaceuticals Inc (NASDAQ:ALNA) released its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.26) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.01.
View Allena Pharmaceuticals' earnings history
.

What price target have analysts set for ALNA?

7 analysts have issued 12-month target prices for Allena Pharmaceuticals' stock. Their forecasts range from $4.00 to $18.00. On average, they expect Allena Pharmaceuticals' stock price to reach $9.67 in the next year. This suggests a possible upside of 632.3% from the stock's current price.
View analysts' price targets for Allena Pharmaceuticals
.

Are investors shorting Allena Pharmaceuticals?

Allena Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 1,430,000 shares, an increase of 31.2% from the August 15th total of 1,090,000 shares. Based on an average trading volume of 1,320,000 shares, the days-to-cover ratio is currently 1.1 days.
View Allena Pharmaceuticals' Short Interest
.

Who are some of Allena Pharmaceuticals' key competitors?

What other stocks do shareholders of Allena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Acasti Pharma (ACST), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD), VBI Vaccines (vbiv) and Miragen Therapeutics (MGEN).

Who are Allena Pharmaceuticals' key executives?

Allena Pharmaceuticals' management team includes the following people:
  • Dr. Alexey L. Margolin, Co-Founder & Chairman (Age 67, Pay $427.95k)
  • Dr. Louis Brenner, Pres, CEO & Director (Age 50, Pay $507.28k)
  • Mr. Edward J. Wholihan, Chief Financial Officer (Age 60, Pay $387.03k)
  • Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 55)
  • Mr. Hugh Wight, Sr. VP of Technical Operations

When did Allena Pharmaceuticals IPO?

(ALNA) raised $80 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Allena Pharmaceuticals' stock symbol?

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

Who are Allena Pharmaceuticals' major shareholders?

Allena Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Sabby Management LLC (6.19%), Worth Venture Partners LLC (1.03%), Jacobs Levy Equity Management Inc. (0.33%), Wedbush Securities Inc. (0.20%), Goldman Sachs Group Inc. (0.11%) and Advisor Group Holdings Inc. (0.08%).
View institutional ownership trends for Allena Pharmaceuticals
.

Which major investors are selling Allena Pharmaceuticals stock?

ALNA stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., and Algert Global LLC.
View insider buying and selling activity for Allena Pharmaceuticals
.

Which major investors are buying Allena Pharmaceuticals stock?

ALNA stock was acquired by a variety of institutional investors in the last quarter, including Sabby Management LLC, Worth Venture Partners LLC, Goldman Sachs Group Inc., Wedbush Securities Inc., and Advisor Group Holdings Inc..
View insider buying and selling activity for Allena Pharmaceuticals
.

How do I buy shares of Allena Pharmaceuticals?

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Allena Pharmaceuticals' stock price today?

One share of ALNA stock can currently be purchased for approximately $1.32.

How big of a company is Allena Pharmaceuticals?

Allena Pharmaceuticals has a market capitalization of $50.32 million. The company earns $-47,340,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis. Allena Pharmaceuticals employs 34 workers across the globe.

What is Allena Pharmaceuticals' official website?

The official website for Allena Pharmaceuticals is www.allenapharma.com.

How can I contact Allena Pharmaceuticals?

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.